CSF3 and Miyoshi myopathy: Based on these results, an ongoing multicenter trial aimed to assess the safety and efficacy of burixafor (GPC-100) and propranolol with and without G-CSF for the mobilization of stem cells in patients with MM undergoing ASCT is now recruiting.